# Alexander Casdin

> Alexander Casdin is the Chief Executive Officer of Epirium Bio, a San Diego biotechnology company developing small-molecule therapies to improve muscle function. A healthcare executive and institutional investor with more than 25 years in the industry, he stepped up from CFO and COO to CEO on January 1, 2025, the same month Epirium's lead drug MF-300 - a first-in-class oral 15-PGDH inhibitor for sarcopenia - cleared the FDA to begin human trials. Before Epirium he founded and ran Reneo Capital Management, was CFO of Sophiris Bio, and ran VP of Finance at Amylin Pharmaceuticals, and he sits on the board of Erasca as audit committee chair.

- **Role:** Chief Executive Officer at Epirium Bio
- **Organizations:** Epirium Bio, Reneo Capital Management LP, Sophiris Bio, Amylin Pharmaceuticals, Casdin Advisors LLC, Cooper Hill Partners LLC, Pequot Capital Management, Dreyfus Corporation, Erasca, Inc.
- **Nationality:** American
- **Education:** M.B.A. (Beta Gamma Sigma), Columbia Business School, B.A., Political Science, Brown University
- **Known for:** Named CEO of Epirium Bio effective January 1, 2025, Founded Reneo Capital Management LP, a healthcare investment fund, Shepherded Epirium's lead candidate MF-300 to FDA IND clearance for sarcopenia

## Career timeline

- **Early career** — Senior managing analyst at the Dreyfus Corporation covering pharmaceuticals, biotechnology, and medical devices
- **Earlier** — Portfolio manager of Pequot Capital Management's healthcare fund
- **Earlier** — CEO and portfolio manager at Cooper Hill Partners LLC, a healthcare investment fund
- **Earlier** — Founder and senior advisor at Casdin Advisors LLC
- **Earlier** — Vice President of Finance at Amylin Pharmaceuticals
- **Earlier** — Chief Financial Officer of Sophiris Bio, Inc.
- **2018** — Joined the board of directors of Erasca; later named Chair of the Audit Committee
- **Pre-2020** — Founder, CEO and portfolio manager of Reneo Capital Management LP
- **2020-10** — Appointed Chief Financial Officer of Epirium Bio
- **2023** — Appointed to the board of directors of Sientra, Inc.
- **2024** — Served as Chief Operating Officer of Epirium Bio
- **2025-01** — Became Chief Executive Officer of Epirium Bio as MF-300 cleared the FDA for Phase 1 trials

## Achievements

- Named CEO of Epirium Bio effective January 1, 2025
- Founded Reneo Capital Management LP, a healthcare investment fund
- Shepherded Epirium's lead candidate MF-300 to FDA IND clearance for sarcopenia
- Serves as Audit Committee Chair on the board of Erasca, Inc.
- Former board member of Ignyta (acquired by Roche) and Dusa Pharmaceuticals (acquired by Sun Pharma)
- Graduated Beta Gamma Sigma from Columbia Business School

## Latest updates

- **2025-01** — Became Chief Executive Officer of Epirium Bio, succeeding Russell Cox who moved to Executive Chairman.
- **2024-12** — Epirium received FDA IND clearance for MF-300 and began a Phase 1 dose-escalation study in healthy participants.

## Links

- Website: https://epirium.com
- LinkedIn: http://www.linkedin.com/in/alexander-casdin-a4457655

---

Profile page: https://yespress.io/alexander-casdin
Published by YesPress — https://yespress.io
Last updated: 2026-06-14